Ginkgo Bioworks Holdings (DNA) Restructuring Costs (2024 - 2025)
Ginkgo Bioworks Holdings (DNA) posted Restructuring Costs of $706000.0 for Q4 2025, down 59.54% on a QoQ basis from $1.7 million in Q3 2025, and down 83.02% year-over-year from $4.2 million in Q4 2024.
Ginkgo Bioworks Holdings (DNA) Restructuring Costs (2024 - 2025) Analysis & Trends
Ginkgo Bioworks Holdings' Restructuring Costs history runs 2 years deep, the most recent figure standing at $706000.0 for Q4 2025.
- Quarterly Restructuring Costs fell 83.02% year-over-year to $706000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $6.1 million (down 78.64% YoY) and the FY2025 annual result came in at $11.4 million, down 52.85% from the prior year.
- Restructuring Costs was $706000.0 for Q4 2025 at Ginkgo Bioworks Holdings, down from $1.7 million in the prior quarter.
- Across five years, Restructuring Costs topped out at $17.1 million in Q2 2024 and bottomed at $706000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Ginkgo Bioworks Holdings | 441.96 Mn | 298.10 Mn | 16.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 706,000.00 |
| Sep 30, 2025 | 1.75 Mn |
| Jun 30, 2025 | 3.67 Mn |
| Mar 31, 2025 | 4.50 Mn |
| Dec 31, 2024 | 4.16 Mn |
| Sep 30, 2024 | 2.95 Mn |
| Jun 30, 2024 | 17.07 Mn |